Baird Capital leads $12.8M Series B funding round for Houston health tech
Medical device company Saranas Inc. closed a $12.8 million Series B funding round, the firm announced July 19. The Series B round was led by Chicago-based Baird Capital, the venture capital and private equity arm of Milwaukee-based Robert W. Baird& Co. The round also saw participation from Austin, Texas-based S3 Ventures. Houston-based Saranas develops an FDA-approved medical device for early detection and monitoring of internal bleeding complications. Saranas' Early Bird device aims to improve… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 22, 2021 Category: Pharmaceuticals Authors: Chris Mathews Source Type: news

Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
Benny Sorensen appointed Chief Executive Officer and Co-Founder Johan Henrik Faber appointed Chief Technology Officer Financing led by Novo Holdings, HealthCap and RA Capital Management Advancing pipeline of bispecific and monoclonal antibodies with ... Biopharmaceuticals, Venture Capital Hemab , thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2021 Category: Pharmaceuticals Source Type: news

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform
Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases Funding led by Seroba Life Sciences and supported by Théa Open Innovation, eureKARE and e... Biopharmaceuticals, Venture Capital Coave Therapeutics, gene therapy, AAV-Ligand Conjugate, ALIGATER (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2021 Category: Pharmaceuticals Source Type: news

Houston health tech firm Saranas raises $12.8M Series B
Houston-based medical device company Saranas Inc. closed a $12.8 million Series B funding round, the firm announced July 19. The Series B round was led by Chicago-based Baird Capital, the venture capital and private equity arm of Milwaukee-based Robert W. Baird& Co. The round also saw participation from Austin-based S3 Ventures. The Houston-based company develops an FDA-approved medical device for early detection and monitoring of internal bleeding complications. Saranas' Early Bird device aims… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 19, 2021 Category: Health Management Authors: Chris Mathews Source Type: news

Houston health tech firm Saranas raises $12.8M Series B
Houston-based medical device company Saranas Inc. closed a $12.8 million Series B funding round, the firm announced July 19. The Series B round was led by Chicago-based Baird Capital, the venture capital and private equity arm of Milwaukee-based Robert W. Baird& Co. The round also saw participation from Austin-based S3 Ventures. The Houston-based company develops an FDA-approved medical device for early detection and monitoring of internal bleeding complications. Saranas' Early Bird device aims… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 19, 2021 Category: Biotechnology Authors: Chris Mathews Source Type: news

Delaware County life sciences firm lands $60M venture capital investment
A Delaware County life sciences company that recently launched its first product has raised $60 million through a private stock sale. Mobilion Systems Inc.'s Series C financing was led by D1 Capital Partners of New York. Existing investors aMoon, Agilent Technologies, IP Group, Hostplus and Cultivation Capital also participated in the round. The company, which has about 60 employees, previously raised $50.4 million from its fir st two investments rounds in 2019 and 2020. Founded in 2015, Chadds… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 15, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Q & A with Atlanta ’s Dr. Jay Yadav on new $100M VC fund
Mammoth Scientific, a health science and technology venture capital firm, on July 13 announced the launch of a $100 million venture capital fund. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 14, 2021 Category: American Health Authors: David Allison Source Type: news

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Company is pioneering true "search and replace" gene editing to address the fundamental genetic causes of disease, restore normal gene function, and potentially provide patients with long-lasting cures Company led by Chief Executive Officer Ke... Biopharmaceuticals, Venture Capital Prime Medicine, Prime Editing, gene editing (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 13, 2021 Category: Pharmaceuticals Source Type: news

Single Pass Closes Seed Funding Round
LAKE FOREST, Calif., July 9, 2021 -- (Healthcare Sales & Marketing Network) -- Bill Colone, CEO, announced today the closing of the seed financing round for Single Pass, Inc. (www.singlepass.co). Single Pass has developed the world's first disposable bipo... Devices, Surgery, Venture Capital Single Pass Inc, disposable bipolar electrocautery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 9, 2021 Category: Pharmaceuticals Source Type: news

Startup founded by Trinity alumni moves headquarters from San Antonio
PatchRx, a biotech startup founded by two Trinity University alumni has moved its headquarters out of San Antonio after raising $1.2 million in pre-seed equity funding. The company, formerly known as PATCH Technologies Inc., moved operations to Tulsa after finding better funding opportunities for its smart pill bottle cap and accompanying software technology, its co-founder Andrew Aertker told the Business Journal. Atento Capital, the venture capital firm that led the company's second pre-seed… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 8, 2021 Category: American Health Authors: Jeannette E. Garcia Source Type: news

Theolytics expands Series A financing and welcomes M Ventures as a new investor
Theolytics is harnessing viruses to combat cancer: transforming patients' lives; through world leading science; with a great team OXFORD, England, July 8, 2021 -- (Healthcare Sales & Marketing Network) -- M Ventures – the strategic venture capital arm ... Biopharmaceuticals, Venture Capital Theolytics, oncolytic virus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 8, 2021 Category: Pharmaceuticals Source Type: news

Sirnaomics Secures $105 Million in Series E Financing
Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 1, 2021 -- (Healthcare Sales & Marketing Network) -- Sirnaomics Ltd., a leading bio... Biopharmaceuticals, Venture Capital Sirnaomics, RNAi therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 1, 2021 Category: Pharmaceuticals Source Type: news

Precision medicine startup launches with Eli Lilly deal and $20M in VC funds
A new precision medicine startup has emerged from stealth with a drug licensed from Eli Lilly& Co. and around $20 million in venture capital. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
SINGAPORE, June 18, 2021 -- (Healthcare Sales & Marketing Network) -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round. ... Biopharmaceuticals, Cardiology, Venture Capital Nuevocor, dilated cardiomyopathy, cardiomyopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2021 Category: Pharmaceuticals Source Type: news

Gene-editing startup incubated at Google goes public in $267M IPO
Verve Therapeutics, a cholesterol-targeting, gene-editing startup that's the first biotech to be incubated by the venture capital arm of Google, has hit the public market in a $267 million IPO — more than twice what it was originally hoping to raise. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 17, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
FREDERICK, Md., June 16, 2021 -- (Healthcare Sales & Marketing Network) -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical... Biopharmaceuticals, Venture Capital Veralox Therapeutics, 12-lipoxygenase, heparin-induced thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2021 Category: Pharmaceuticals Source Type: news

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of the Company's preclinical pipeline... Biopharmaceuticals, Oncology, Venture Capital KAHR Medical, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2021 Category: Pharmaceuticals Source Type: news

Cambridge RNA startup raises $45M to break into CNS, liver disease
Five-year-old Cambridge startup Camp4 Therapeutics has quietly spent the last few years developing new, early-stage treatments centered around RNA. Now it's got a fresh round of $45M in venture capital to take its lead compounds into the clinic. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 15, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Flagship Pioneering triples size of latest fund after reopening to investors
Earlier this spring, Flagship Pioneering decided to reopen its latest fund for further investment. In just two months' time, it nearly tripled that fund's size, easily a record for the venture capital and creation firm. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 14, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

Venture capital firm Iter Investments bets next pharma fortune is in psychedelics
The global race to commercialize psychedelic drugs has arrived. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 11, 2021 Category: Health Management Authors: Ashley Portero Source Type: news

Venture capital firm Iter Investments bets next pharma fortune is in psychedelics
The global race to commercialize psychedelic drugs has arrived. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 11, 2021 Category: Biotechnology Authors: Ashley Portero Source Type: news

Senda Biosciences Announces Closing of $98 Million Series B Financing
Funding to accelerate development of its platform and therapeutic programs CAMBRIDGE, Mass., June 10, 2021 -- (Healthcare Sales & Marketing Network) -- Senda Biosciences, a company that is systematically harnessing the powerful molecular interactions t... Biopharmaceuticals, Venture Capital Senda Biosciences (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 10, 2021 Category: Pharmaceuticals Source Type: news

ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes
Brings the Company's total Series D funding to more than $115 million SAN DIEGO, June 9, 2021 -- (Healthcare Sales & Marketing Network) -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million finan... Regenerative Medicine, Venture Capital ViaCyte, cell therapy, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 9, 2021 Category: Pharmaceuticals Source Type: news

Prytime Medical Closes Oversubscribed $6M Inside Funding Round to Fuel Commercialization Growth
The capital will be used to accelerate the commercialization of Prytime Medical's new line of minimally invasive REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) hemorrhage control products. SAN ANTONIO, June 2, 2021 -- (Healthcare Sale... Devices, Venture Capital Prytime Medical, REBOA catheter, hemorrhage, truncal hemorrhage (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 2, 2021 Category: Pharmaceuticals Source Type: news

Google Ventures' first biotech startup files for IPO
Verve Therapeutics, a cholesterol-targeting, gene-editing startup and the first biotech to be incubated by the venture capital arm of Google, is planning to go public in a $100 million IPO. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 1, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
SEATTLE, June 1, 2021 -- (Healthcare Sales & Marketing Network) -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the close of its $10 million financing round. Kineta i... Biopharmaceuticals, Oncology, Venture Capital, Personnel Kineta, anti-VISTA antibody (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2021 Category: Pharmaceuticals Source Type: news

VC firm seeking $50M to invest in women ’s health technology
A new venture capital firm formed to invest in women ’s health technology is seeking to raise $50 million for its funding pool. The company, FemHealth Ventures, said it plans to make 15 investments from the fund. Maneesha Ghiya and partner Noraan Sadik formed Short Hills, New Jersey-based FemHealth Ventures in August of 2020 to fund companies tar geting treatments and cures for conditions appearing only in women, like endometriosis, polycystic ovarian syndrome and cervical cancer; mostly in women,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 30, 2021 Category: Pharmaceuticals Authors: Anne Stych Source Type: news

VC firm seeking $50M to invest in women ’s health technology
A new venture capital firm formed to invest in women ’s health technology is seeking to raise $50 million for its funding pool. The company, FemHealth Ventures, said it plans to make 15 investments from the fund. Maneesha Ghiya and partner Noraan Sadik formed Short Hills, New Jersey-based FemHealth Ventures in August of 2020 to fund companies tar geting treatments and cures for conditions appearing only in women, like endometriosis, polycystic ovarian syndrome and cervical cancer; mostly in women,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 30, 2021 Category: Biotechnology Authors: Anne Stych Source Type: news

True Wealth Ventures to raise $30M second fund to back women-led companies
As venture funding levels for women-led companies plunge even further below their male counterparts, Sara Brand and Kerry Rupp are investing where they can to reverse the trend. The True Wealth Ventures general partners on May 27 filed paperwork with the U.S. Securities and Exchange Commission showing the Austin venture capital firm plans to raise a $30 million second fund. SEC rules prohibit VCs from speaking about raising capital for an investment fund of this type. Co mmission regulations cap… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 28, 2021 Category: Pharmaceuticals Authors: Mike Cronin Source Type: news

Digital health management company Hello Heart completes $45 million Series C round
Digital health management company Hello Heart has completed a $45 million Series C to drive growth. The round was led by later-stage venture capital and growth equity firm IVP, which also has invested in companies including Coinbase, Lyra Health, Slack, Snap, and Twitter. Somesh Dash, an IVP general partner, will join the company’s board of directors. Hello Heart’s existing investors, incl uding Khosla Ventures, BlueRun Ventures, Maven Ventures, and Resolute Ventures also participated in the… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 26, 2021 Category: American Health Authors: Anne Stych Source Type: news

Eliem Therapeutics Announces $60 Million Series B Financing
Advances two clinical programs through topline data across four indications Progresses two preclinical programs to potential lead candidate selection Brings total funding since inception to $140 million SEATTLE and CAMBRIDGE, England, May 24, 2021... Biopharmaceuticals, Neurology, Venture Capital Eliem Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2021 Category: Pharmaceuticals Source Type: news

BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs on track for IND-enabling activities in 2022 Multi kinase inhibitor, BTX-A51, to continue in Phase 1 with expansion into s... Biopharmaceuticals, Oncology, Venture Capital BioTheryX, protein homeostasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 20, 2021 Category: Pharmaceuticals Source Type: news

Healthcare Start-Up Ro to Acquire Modern Fertility
The parent of Roman, a digital health clinic for men, announced that it would acquire a firm that offers at-home fertility tests for women. (Source: NYT Health)
Source: NYT Health - May 19, 2021 Category: Consumer Health News Authors: Alisha Haridasani Gupta Tags: Women and Girls Medicine and Health Venture Capital Start-ups Telemedicine Roman Health Ventures Inc Mergers, Acquisitions and Divestitures Source Type: news

Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atla... Biopharmaceuticals, Ophthalmology, Venture Capital Vedere Bio II, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 18, 2021 Category: Pharmaceuticals Source Type: news

Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
Oversubscribed round co-led by Cormorant Asset Management and Fairmount Funds, supported by a strong syndicate of new and existing investors PHILADELPHIA, May 18, 2021 -- (Healthcare Sales & Marketing Network) -- Interius BioTherapeutics, a preclinical... Biopharmaceuticals, Venture Capital Interius BioTherapeutics, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 18, 2021 Category: Pharmaceuticals Source Type: news

Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers Company's proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more effica... Biopharmaceuticals, Oncology, Venture Capital, Personnel Soteria Biotherapeutics, bispecific T-cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 17, 2021 Category: Pharmaceuticals Source Type: news

Una revoluci ón psicodélica llega a la psiquiatría
La psilocibina y el MDMA est án a punto de convertirse en las nuevas terapias de moda, algo que no se veía desde el Prozac. Las universidades quieren participar, al igual que Wall Street. Algunas personas están preocupadas por la posibilidad de que la presión para liberalizar el acceso pueda tener consecuencias no deseadas. (Source: NYT Health)
Source: NYT Health - May 15, 2021 Category: Consumer Health News Authors: Andrew Jacobs Tags: Psilocybin Mushrooms LSD (Lysergic Acid Diethylamide) Ecstasy (Drug) Anxiety and Stress Mental Health and Disorders Venture Capital Depression (Mental) Research Alternative and Complementary Medicine Psychiatry and Psychiatrists Post-T Source Type: news

Healionics Raises $4.7M Equity Round to Support Commercialization of Stargraft Vascular Graft
SEATTLE, May 13, 2021 -- (Healthcare Sales & Marketing Network) -- Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversio... Devices, Venture Capital Healionics, STARgraft, vascular graft (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2021 Category: Pharmaceuticals Source Type: news

SpliSense Secures $28.5 Million in Series B Financing
Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases JERUSALEM, May 13, 2021 -- (He... Biopharmaceuticals, Venture Capital SpliSense, Cystic Fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2021 Category: Pharmaceuticals Source Type: news

Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Financing Led by Bain Capital Life Sciences - Andrew Hack, M.D., Ph.D., a Managing Director of Bain Capital Life Sciences, to Join Nuvalent Board of Directors Funding to Advance Parallel Lead Programs in ROS1-positive and ALK-positive NSCLC to Phase 1/2... Biopharmaceuticals, Oncology, Venture Capital Nuvalent, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 11, 2021 Category: Pharmaceuticals Source Type: news

Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications LOS ANGELES, May 11, 2021 -- (Healthcare Sales & Marketing Network) -- Appia Bio, ... Biopharmaceuticals, Venture Capital, Personnel Appia Bio , allogeneic cell therapies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 11, 2021 Category: Pharmaceuticals Source Type: news

How MDMA and Psilocybin Became Hot Investments
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences. (Source: NYT Health)
Source: NYT Health - May 10, 2021 Category: Consumer Health News Authors: Andrew Jacobs Tags: Psilocybin Mushrooms LSD (Lysergic Acid Diethylamide) Ecstasy (Drug) Anxiety and Stress Mental Health and Disorders Venture Capital Depression (Mental) Research Alternative and Complementary Medicine Psychiatry and Psychiatrists Post-T Source Type: news

BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
SUNNYVALE, Calif., May 5, 2021 -- (Healthcare Sales & Marketing Network) -- BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undrugga... Biopharmaceuticals, Oncology, Venture Capital BridGene Biosciences, IMTAC, chemoproteomic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 5, 2021 Category: Pharmaceuticals Source Type: news

Pappas Capital scores again as Pfizer grabs portfolio company
Durham-based venture capital firm Pappas Capital has successfully ushered another company exit from its portfolio. And the hits are expected to keep coming. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 30, 2021 Category: Biotechnology Authors: Sonia Waraich Source Type: news

Pappas Capital scores again as Pfizer grabs portfolio company
Durham-based venture capital firm Pappas Capital has successfully ushered another company exit from its portfolio. And the hits are expected to keep coming. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 30, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Blue Therapeutics announces Series A raise
Unveiling disruptive IND stage receptor-interactomicsTM platform and pipeline WALTHAM, Mass., April 30, 2021 -- (Healthcare Sales & Marketing Network) -- Blue Therapeutics is a Boston based drug discovery and development company. The lead asset BLUE-18... Biopharmaceuticals, Venture Capital Blue Therapeutics, receptor-interactomics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2021 Category: Pharmaceuticals Source Type: news

Capsida Biotherapeutics Debuts with $140 Million of Capital
Versant, Westlake Village BioPartners launch next-generation gene therapy company with $50 million Series A Collaboration with AbbVie provides $90 million in up front and equity investment capital to create tissue-targeted gene therapies for three CNS d... Biopharmaceuticals, Venture Capital Capsida Biotherapeutics, AbbVie (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 29, 2021 Category: Pharmaceuticals Source Type: news

Microsure raises € 2.7 million under new leadership for the further development and clinical roll-out of the MUSA microsurgery robot assistant
Round led by impact investor Invest-NL and supported by existing shareholders BOM Brabant Ventures, Innovation Industries and private investor TCIM New CEO Sjaak Deckers appointed to lead the company into its next market phase SON, Netherlands, April... Devices, Surgery, Venture Capital Microsure, micro-surgical robotics, MUSA , robotic surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 29, 2021 Category: Pharmaceuticals Source Type: news

Caresyntax Raises $100 Million to Make Surgery Smarter and Safer
Investment will strengthen technology and expand company's reach BOSTON, April 28, 2021 -- (Healthcare Sales & Marketing Network) -- Caresyntax, the leading enterprise-level digital surgery platform delivering actionable insights to make surgery smarte... Devices, Surgery, Venture Capital Caresyntax, digital surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 28, 2021 Category: Pharmaceuticals Source Type: news

Two Einstein Research Teams Secure Funding from Venture Capital
April 27, 2021—(BRONX, NY)—Two teams of scientists at Albert Einstein College of Medicine have secured $100,000 X-Seed Awards—part of a new program supporting early-stage life-science projects that have startup potential. The funding comes from the Deerfield Management Company, a healthcare investment firm that is coordinating with local government agencies to promote life sciences in New York City. (Source: Einstein News)
Source: Einstein News - April 27, 2021 Category: Universities & Medical Training Source Type: news